Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.404 | ElevatION: CRC-101: A Phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic MSS colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2014.357 | A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED WITH ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADVANCED NON−SMALL CELL LUNG CANCER | Prof. MA Brigette Buig Yue |
| 2017.247 | Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.357 | A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2016.385 | A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2016.443 | A PHASE III, OPEN LABEL, MULTICENTER, THREE-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY VS. REGORAFENIB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2023.455 | Multi-modal Deep Learning of Multiomics Profiles, Radiology and Histopathology Images to Advance Colorectal Cancer Classification for Precision Oncology |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2022.413 | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2020.591 | AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2022.408 | Clinical application of circulating tumour DNA (ctDNA) assay for monitoring treatment response in advanced gastrointestinal cancers (‘PROCURE-liquid’ program) | Prof. MA Brigette Buig Yue |
| 2023.373 | A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma | Prof. MA Brigette Buig Yue |
| 2021.556 | A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2021.630 | An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus- Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette Buig Yue |
| 2020.457 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB IN COMBINATION WITH PACLITAXEL AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, UNRESECTABLE RECURRENT, OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 教授 |
| 2019.327 | A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.342 | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.367 | A FIRST IN-HUMAN, PHASE 1/2 STUDY OF CFI-402411, HEMATOPOIETIC PROGENITOR KINASE-1 (HPK1) INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2018.436 | A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.002 | A phase I/Ib, open-label, multi-center, study of DKY709 as a single agent and in combination with PDR001 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.684 | An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.168 | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2026.235 | A randomized, open label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03) | Prof. MA Brigette Buig Yue |
| 2025.386 | A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) | Prof. MA Brigette Buig Yue |
| 2025.202 | A PHASE I DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY CLINICAL ACTIVITY OF RO7673396 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING RAS MUTATION(S) | Prof. MA Brigette Buig Yue |
| 2024.095 | A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors | Prof. MA Brigette Buig Yue |
| 2025.375 | tReatment Individualisation By EBV stratificatiON in nasopharyngeal carcinoma: an umbrella platform study (RIBBON-Umbrella) | Prof. MA Brigette Buig Yue |
| 2025.199 | A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy or in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors | Prof. MA Brigette Buig Yue |
| 2024.483 | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | Prof. MA Brigette Buig Yue |
| 2025.362 | Phase I-II study of JS207 a bispecific antibody against PD1-VEGF in the treatment of recurrent/metastatic nasopharyngeal carcinoma | Prof. MA Brigette Buig Yue |
| 2024.063 | NRG-HN011: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB VERSUS NIVOLUMAB AND BMS-986016 (RELATLIMAB) AS MAINTENANCE TREATMENT AFTER FIRST-LINE TREATMENT WITH PLATINUM-GEMCITABINE-NIVOLUMAB FOR PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA (REMAIN) | Prof. MA Brigette Buig Yue |
| 2024.647 | A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Prof. MA Brigette Buig Yue |
| 2024.659 | A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2017.540 | A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.153 | A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.054 | A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2010.251 | Uncontrolled, open-label, non-randomized, phase 1 study to investigate the pharmacokinetics, safety, tolerability, and efficacy of BAY 73-4506 in Chinese patients with advanced, refractory solid tumors | Associate Professor Ma Brigette Buig-Yue |
| 2010.473 | An East Asian phase I, multicenter, open-label, dose-escalation study of oral LDE225 in patients with advanced solid tumors | Associate Prof. Ma Buig Yue Brigette |
| 2025.419 | EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease |
Prof. MA Ching Wan 馬青雲 |
| 2025.544 | A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants with Dyslipidaemia (AZURE-CHINA) |
Prof. MA Ching Wan 馬青雲 |
| 2010.466 | SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus A Multicenter, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes | Professor Ma Ching Wan Ronald |
| 2012.052 | An evaluation on the effectiveness, acceptability and pricing of annual complication assessment for people with diabetes mellitus in the Hong Kong Community | Prof Ma Ching-wan, Ronald |
| 2011.506 | Transvaginal ultrasound probe contamination by the Human Papillomavirus in the Emergency Department | Dr. MA Christine Shuk Ting |
| 2017.282 | Mindfulness-based cognitive therapy for community-dwelling adults with anxiety symptoms: An exploration of efficacy and cognitive mechanism |
Miss MA Duan Yang 馬端陽 |
| 2012.321 | An opinion Survey among frail elderly patients and their carers regarding their opinion about self-financed community care services | Dr MA HON MING |
| 2009.415 | A Cohort Study on the Clinical Outcomes of Elderly Patients Admitted for Community Acquired Pneumonia (CAP) | Dr. MA Hon Ming |
| 2023.153 | Mitochondrial disease related mortality - evaluation of a large international cohort | Dr. MA Kam Hung |
| 2013.407 | Pharmacokinetic study of once-daily formulation of Tacrolimus (Advagraf_) in Chinese kidney transplant patients | Dr Ma King Wing, Terry |
| 2022.043 | Effects of a structured Tai Chi program on improving physical activity level, exercise self-efficacy, and health outcomes among pregnant women: A randomised controlled trial |
Ms. MA Nan 马楠 |
| 2015.241 | A Transdiagnostic Anger Management Program for Adult Psychiatric Inpatient |
Ms. MA Olivia 馬婉婷 |
| 2015.458 | The effect of imagery and rumination on depression: a mediation and intervention study |
Ms. MA Olivia 馬婉婷 |
Page 177 of 289.

